Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side
Medexus Pharmaceuticals IncFebruary 16, 2021 GMT
TORONTO, CHICAGO and MONTREAL, Feb. 16, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16th – February 19th, 2021.
Ken d’Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to present on Wednesday, February 17, 2021 at 9:30 AM, Eastern Time. The presentation will be webcast live and available for replay here. One-on-one meetings will be held throughout the conference via video conference calls.
Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®
TORONTO, CHICAGO and MONTREAL, Jan. 25, 2021 Medexus Pharmaceuticals Inc. (the “
Company” or
announced today that it has renewed and expanded its distribution agreement for NYDA
®, a market leading treatment for head lice, through September 26, 2026. The agreement with G. Pohl-Boskamp GmbH & Co KG (“
Pohl-Boskamp“) provides the Company with exclusive Canadian distribution rights for NYDA® and includes a commitment related to bringing new and innovative solutions to the Canadian market. The initial agreement with Pohl-Boskamp was signed in 2011 and the first extension was announced in June 2015.
Richard Labelle, Vice President Allergy, Pediatric and OTC Portfolios, commented, “The renewal and expansion of the agreement is the result of the solid relationship established over the years and based on the success achieved by NYDA
Medexus Submits Application to List on the Nasdaq
TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 Medexus Pharmaceuticals Inc. (the “
Company” or
“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)
announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “
Nasdaq”).
Ken d’Entremont, Chief Executive Officer of Medexus, commented, “The submission of our application to list on the Nasdaq marks a significant milestone for Medexus. We believe we now meet the initial listing requirements, which reflects the success of our ongoing efforts to create a highly scalable business platform with a diversified and growing product portfolio across North America. In fact, we have grown at a 129% CAGR over the past 3 fiscal years alone and are generating very strong cash flow. Given our current trajectory and growth of our U.S-based business that now accounts for more than 74% of total revenues, management and the board of direct
Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.